BTG3 and Autoimmunity: Low dose application of the TLR7 agonist IMQ treatment exerted a mild but significant effect to promote features of autoimmunity in FVB/N mice in the current study, including splenomegaly and significantly increased plasma ANA antibody levels, although these remained variable and below the positive index in many of the mice.